Breast Medical Oncology ...

Dr. Karng S. Log

Claim this profile

Lutheran Hospital - Cancer Centers of Colorado

Studies Small Cell Lung Cancer
Studies Colon Cancer
10 reported clinical trials
32 drugs studied

Area of expertise

1Small Cell Lung Cancer
Karng S. Log has run 2 trials for Small Cell Lung Cancer.
2Colon Cancer
Karng S. Log has run 2 trials for Colon Cancer. Some of their research focus areas include:
Stage II
Stage III
MSS positive

Affiliated Hospitals

Image of trial facility.
Lutheran Hospital - Cancer Centers Of Colorado
Image of trial facility.
SCL Health Saint Joseph Hospital

Clinical Trials Karng S. Log is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Lomustine + Standard Therapy

for Glioblastoma

This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting2 awards Phase 34 criteria

More about Karng S. Log

Clinical Trial Related2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Karng S. Log has experience with
  • Oxaliplatin
  • MFOLFIRINOX
  • Carboplatin/Cisplatin-Etoposide
  • HLX10
  • Prophylactic Cranial Irradiation (PCI)
  • Thoracic Radiotherapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Karng S. Log specialize in?
Is Karng S. Log currently recruiting for clinical trials?
Are there any treatments that Karng S. Log has studied deeply?
What is the best way to schedule an appointment with Karng S. Log?
What is the office address of Karng S. Log?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security